Prevalence of sarcopenia in community-dwelling older adults using the updated EWGSOP2 definition according to kidney function and albuminuria

Moreno-González, Rafael; Corbella, Xavier; Mattace-Raso, Francesco; Tap, Lisanne; Sieber, Cornel; Freiberger, Ellen; Kostka, Tomasz; Guligowska, Agnieszka; Melzer, Itshak; Melzer, Yehudit; Carlsson, Axel C.; Ärnlöv, Johan; Roller‐Wirnsberger, Regina; Wirnsberger, Gerhard; Gil, Pedro; Martínez, Sara Laínez; Fabbietti, Paolo; Corsonello, Andrea; Lattanzio, Fabrizia; Formiga, Francesç

doi:10.1186/s12877-020-01700-x

Cited by 32 publications

(32 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sarcopenia prevalence (probable/confirmed/severe sarcopenia) was 18.1% ( n = 81) at baseline, when using the revised EWGSOP2 definition. The prevalence of sarcopenia in our population‐based sample of middle‐aged and older men is similar to the findings of Moreno‐Gonzalez et al 31 . In their study with 1420 European community‐dwelling older adults (>75 years), 22.1% of men could be classified into one of the sarcopenia categories of EWGSOP2 31 .…”

Section: Discussionsupporting

confidence: 90%

“…The prevalence of sarcopenia in our population‐based sample of middle‐aged and older men is similar to the findings of Moreno‐Gonzalez et al . 31 In their study with 1420 European community‐dwelling older adults (>75 years), 22.1% of men could be classified into one of the sarcopenia categories of EWGSOP2. 31 Sarcopenia prevalence and incidence in EMAS, according to other definitions [International Working Group on Sarcopenia (IWGS), EWGSOP1, Baumgartner], have been described elsewhere.…”

Section: Discussionmentioning

confidence: 99%

“… 31 In their study with 1420 European community‐dwelling older adults (>75 years), 22.1% of men could be classified into one of the sarcopenia categories of EWGSOP2. 31 Sarcopenia prevalence and incidence in EMAS, according to other definitions [International Working Group on Sarcopenia (IWGS), EWGSOP1, Baumgartner], have been described elsewhere. 20 When we apply the EWGSOP2 criteria in these EMAS analyses, prevalence and incidence were higher as compared with previous sarcopenia definitions.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Inflammatory markers are associated with quality of life, physical activity, and gait speed but not sarcopenia in aged men (40–79 years)

Dupont

LʼAbbate

Dedeyne

et al. 2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Background Age‐related chronic low‐grade inflammation (inflammaging) is one of the proposed mechanisms behind sarcopenia. However, findings regarding inflammatory markers in sarcopenic older adults are conflicting. This study aimed to determine the association between inflammatory markers, prevalent as well as incident sarcopenia, sarcopenia‐defining parameters, quality of life (QoL), and physical activity in middle‐aged and older men. Methods Men aged 40–79 years (mean 59.66 ± 11.00y) were recruited from population registers in eight European centres for participation in the European Male Aging study (EMAS). Subjects were assessed at baseline (2003–2005) and again after a median follow‐up of 4.29 years. In 2577 participants, associations between baseline inflammatory markers [high‐sensitive C‐reactive protein (hs‐CRP), white blood cell count (WBC), albumin] and baseline physical activity (PASE) and QoL (SF‐36) were analysed. In the Leuven and Manchester cohort (n = 447), data were available on muscle mass (whole‐body dual X‐ray absorptiometry) and strength. In this subgroup, cross‐sectional associations between baseline inflammatory markers and sarcopenia‐defining parameters (handgrip strength, chair stand test, appendicular lean mass, and gait speed) and prevalent sarcopenia were examined. In a further subgroup (n = 277), associations with knee extensor strength were explored. Longitudinally, predictive value of baseline inflammation on functional decline, physical activity, QoL, and incident sarcopenia was examined. Subgroup analyses were performed in subgroups with chronic inflammation and stratified by age. Linear and logistic regressions were used, adjusted for age, body mass index, centre, and smoking. Results At baseline, hs‐CRP and WBC were negatively associated with PASE score (hs‐CRP: β = −7.920, P < 0.001; and WBC: β = −4.552, P < 0.001) and the physical component score of SF‐36 (hs‐CRP: β = −1.025, P < 0.001; and WBC: β = −0.364, P < 0.001). Baseline WBC levels were negatively associated with gait speed (β = −0.013; P = 0.025), quadriceps isometric 90° (β = −5.983; P = 0.035) and isokinetic 60°/s peak torque/body weight (β = −5.532; P = 0.027). The prevalence of sarcopenia at baseline was 18.1% (n = 81). Of those without sarcopenia at baseline, 64 (18.6%) satisfied criteria for sarcopenia at follow‐up. There were no significant associations between baseline inflammatory markers and either prevalent or incident sarcopenia, or change in level of sarcopenia‐defining parameters between baseline and follow‐up. Conclusions In middle‐aged and older men, hs‐CRP and WBC were negatively associated with QoL and PASE scores, while WBC was negatively associated with gait speed and knee strength. Associations with hs‐CRP remained significant in all ages, whereas WBC levels were only associated with PASE, gait speed and knee strength in older adults (60–79 years). Baseline inflammatory markers (hs‐CRP, WBC and albumin) did not predict functional decline, decline in physical activity, decreased QoL or incid...

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory markers are associated with quality of life, physical activity, and gait speed but not sarcopenia in aged men (40–79 years)

Dupont

LʼAbbate

Dedeyne

et al. 2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

show abstract

“…Lee et al 145) analyzed the nationwide prospective cohort of CKD in Korea and reported that normal body mass index with central obesity has increased risk of coronary artery calcification, and adipose tissue volume has a significant correlation with VC. 146) 147) In addition, the prevalence of low muscle mass is increased as CKD is more advanced 148) and sarcopenia in hemodialysis patients shows an independent relationship with VC. 149) These results suggest that pathogenesis of obesity, sarcopenia and VC may involve some shared mechanism, and inflammation is potential common pathway of them.…”

Section: Clinical Implication Of Vascular Calcification In Chronic Kidney Diseasementioning

confidence: 99%

Vascular Calcification in Chronic Kidney Disease: Distinct Features of Pathogenesis and Clinical Implication

Kim

Hwang

2021

Korean Circ J

View full text Add to dashboard Cite

Author's summary Vascular calcification (VC) is highly prevalent in patients with chronic kidney disease (CKD) and leads to increased cardiovascular morbidity and mortality. In patients with CKD, traditional factors do not fully explain the high prevalence of VC. This suggests that a CKD-specific pathobiology is involved in the development of VC and mounting evidence indicates that VC in CKD patients has distinct features of clinical presentation and that clinical implications are changed compared to those in the general population. In this review, we discuss the mechanism, diagnostic imaging modalities, clinical features and implications, and management of VC in patients with CKD.

show abstract

“…Chronic kidney disease (CKD) is often called a model of ‘accelerated ageing’; therefore, it is likely that the loss of lean mass, reduced skeletal muscle strength, and low physical performance (all components of sarcopenia) are in the same direction as patient‐centred outcomes of ageing such as mobility limitations, disability, and mortality as in the general population 22 . Although some criteria have been developed to define sarcopenia, 4 the feasibility of using such criteria in CKD patients has not yet been clarified yet 23 . The type of test used to detect sarcopenia may influence the diagnosis of sarcopenia in CKD patients 24 .…”

Section: Introductionmentioning

confidence: 99%

Effects of hormonal changes on sarcopenia in chronic kidney disease: where are we now and what can we do?

Güngör

Ulu

Hasbal

et al. 2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Sarcopenia or muscle wasting is a progressive and generalized skeletal muscle disorder involving the accelerated loss of muscle mass and function, often associated with muscle weakness (dynapenia) and frailty. Whereas primary sarcopenia is related to ageing, secondary sarcopenia happens independent of age in the context of chronic disease states such as chronic kidney disease (CKD). Sarcopenia has become a major focus of research and public policy debate due to its impact on patient's health‐related quality of life, health‐care expenditure, morbidity, and mortality. The development of sarcopenia in patients with CKD is multifactorial and it may occur independently of weight loss or cachexia including under obese sarcopenia. Hormonal imbalances can facilitate the development of sarcopenia in the general population and is a common finding in CKD. Hormones that may influence the development of sarcopenia are testosterone, growth hormone, insulin, thyroid hormones, and vitamin D. Although the relationship between free testosterone level that is low in uraemic patients and sarcopenia in CKD is not well‐defined, functional improvement may be seen. Unlike testosterone, it is known that vitamin D is associated with muscle strength, muscle size, and physical performance in patients with CKD. Outcomes after vitamin D replacement therapy are still controversial. The half‐life of growth hormone (GH) is prolonged in patients with CKD. Besides, IGF‐1 levels are normal in patients with Stage 4 CKD—a minimal reduction is seen in the end‐stage renal disease. Unresponsiveness or resistance of IGF‐1 and changes in the GH/IGF‐1 axis are the main causes of sarcopenia in CKD. Low serum T3 level is frequent in CKD, but the net effect on sarcopenia is not well‐studied. CKD patients develop insulin resistance (IR) from the earliest period even before GFR decline begins. IR reduces glucose utilization as an energy source by hepatic gluconeogenesis, decreasing muscle glucose uptake, impairing intracellular glucose metabolism. This cascade results in muscle protein breakdown. IR and sarcopenia might also be a new pathway for targeting. Ghrelin, oestrogen, cortisol, and dehydroepiandrosterone may be other players in the setting of sarcopenia. In this review, we mainly examine the effects of hormonal changes on the occurrence of sarcopenia in patients with CKD via the available data.

show abstract

Prevalence of sarcopenia in community-dwelling older adults using the updated EWGSOP2 definition according to kidney function and albuminuria

Cited by 32 publications

References 53 publications

Inflammatory markers are associated with quality of life, physical activity, and gait speed but not sarcopenia in aged men (40–79 years)

Inflammatory markers are associated with quality of life, physical activity, and gait speed but not sarcopenia in aged men (40–79 years)

Vascular Calcification in Chronic Kidney Disease: Distinct Features of Pathogenesis and Clinical Implication

Effects of hormonal changes on sarcopenia in chronic kidney disease: where are we now and what can we do?

Contact Info

Product

Resources

About